Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews
| Autor: | Loretta A. Williams, Samuel S. Payén, Terri Armstrong, Shiao-Pei Weathers, Elizabeth Vera, Alvina Acquaye, Mark R. Gilbert |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Quality of life
medicine.medical_specialty Nausea Brain tumor Health Informatics Brain tumors 03 medical and health sciences 0302 clinical medicine Health Information Management Qualitative research Internal medicine Glioma medicine MDASI-BT business.industry lcsh:Public aspects of medicine Research 030503 health policy & services Qualitative interviews lcsh:RA1-1270 Symptom management medicine.disease Hair loss Patient outcomes 030220 oncology & carcinogenesis Vomiting Itching medicine.symptom 0305 other medical science business |
| Zdroj: | Journal of Patient-Reported Outcomes Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-10 (2019) |
| ISSN: | 2509-8020 |
| DOI: | 10.1186/s41687-019-0143-0 |
| Popis: | Background Identifying symptoms experienced throughout the disease trajectory is pivotal to understanding management of patient symptoms. Patient interviews to solicit input from those who have experienced these symptoms is one method to capture this perspective to validate symptoms included in patient reported outcomes (PRO) measures. Methods A thematic approach was used to identify themes within qualitative interviews. The MD Anderson Symptom Inventory- Brain Tumor (MDASI-BT) was completed by glioma patients. Descriptive statistics was used for analysis of the MDASI-BT. Results Thematic saturation was reached with 23 participants, with a median age of 53 (23–62), on treatment (57%) and diagnosed with a glioblastoma (48%). Patients endorsed 20 out of the 22 MDASI-BT symptoms (symptoms not reported: dry mouth, shortness of breath) during the interviews and with completion of the instrument (seizures and vomiting were not endorsed). Fatigue (55%), seizures (50%), and pain (50%) were common symptoms described by the sample. During treatment, more symptoms were identified with fatigue, hair loss, and nausea more problematic. Aside from itching and swelling (endorsed by 2 patients each), all other symptoms not included in the MDASI-BT instrument were endorsed by only one patient. Conclusions Completion of the MDASI-BT, found patients reported on average 6.8 symptoms with 14% of reported symptoms (mean = 3) rated as moderate to severe. The findings demonstrate how applicable the MDASI-BT is in capturing significant symptoms experienced and how important it is to utilize throughout ones’ care to manage symptoms effectively. Electronic supplementary material The online version of this article (10.1186/s41687-019-0143-0) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink